MAPT and Dravet syndrome: The core CSF biomarkers for AD (Aβ42, p-tau, and t-tau)—which reflect Aβ deposition, neurofibrillary tangle pathology, and AD-related neurodegeneration, respectively [39]—are consistently changed in AD [40,41] and have therefore been in focus when studying AD in DS.